Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 84Breast Neoplasms 10Neoplasm Metastasis 7Neoplasms 5Prostatic Neoplasms, Castration-Resistant 4Prostate Cancer Metastatic 4Metastatic Castration-Resistant Prostate Cancer 4Metastatic Castration-resistant Prostate Cancer 3Castration-resistant Prostate Cancer 3Triple Negative Breast Neoplasms 2Castration Resistant Metastatic Prostate Cancer 2Adenocarcinoma of the Prostate 2Adenocarcinoma 2Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Salivary Cancer 1Recurrent Endometrial Endometrioid Adenocarcinoma 1Prostatic Diseases 1Prostate Carcinoma Metastatic to the Bone 1Prostate Adenocarcinoma 1Primary Breast Cancer ER+ve 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Non-metastatic, Hormone naïve Prostate Cancer 1Non-Muscle Invasive Bladder Neoplasms 1Neoadjuvant Therapy 1NSCLC Harboring NRG1 Fusion 1Metastatic Progressive Castration-resistant Prostate Cancer 1Metastatic Hormone-sensitive Prostate Cancer 1

Interventions

pamiparib 1enzalutamide 1apalutamide 1abiraterone 1Prednisone 1Prednisolone 1Poly(ADP-ribose) Polymerase Inhibitors 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoadjuvant Therapy × enzalutamide × Clear all
NCT05406999 2022-08-16

Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2 Recruiting
900 enrolled
Genitourinary

Neoadjuvant Therapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡